Filing Suggests Bill Hwang Profoundly Pressed Bet in Baidu (BIDU) in Days Before Collapse
- Futures slip as U.S. calls for pause in J&J's single-dose COVID-19 vaccine
- U.S. Calls for Pause of J&J (JNJ) Vaccine After Clotting Cases, Including One Death
- Biggest SPAC Deal Ever: Grab To Go Public in a $40 Billion Merger With Altimeter (AGC), Backed by Fidelity and BlackRock
- Oil prices rise after robust China data
- Bitcoin (BTC) Price Soars 5% to Fresh Record Highs Ahead of Coinbase IPO
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
An interesting 13G filing on Baidu (NASDAQ: BIDU) may shed some light on how much Bill Hwang of Archegos was pressing his bets in the weeks before the funds' collapse on Friday due to margin calls.
The filing after the close of trading Monday from Morgan Stanley, a known Archegos brokerage firm, showed it held 115,126,744 ordinary shares, or 5.2% of BIDU, as of March 18. Translated into ADRs (8:1), this would equal 14,390,843 ADRs. This is more than a 3-fold increase in Morgan Stanley's position of 4,462,203 ADRs owned at the end of 2020.
The stake was worth $3.8 million on March 18, based on BIDU's closing price of $264.85. However, shares of BIDU quickly started moving lower in the days ahead. BIDU hit $239.19 on March 24, $204.57 on March 25, before the major selling occurred on March 26 which pushed shares to an intra-day low of $174.05.
You can see how quickly Hwang's collateral was eaten up by the stock moves if he was running a reported 5x leverage.
As an example, if you assume all of Morgan Stanley BIDU position was Hwang-related, he would have used $760 million in equity for the $3.8 billion stake. The 22.7% drop in BIDU from March 18-24 would have wiped out his entire equity in the stock, triggering a margin call to come up with more equity. Meanwhile, Hwang had similar positions spread out across Wall Street. When the margin clerks came calling, he simply didn't have the capital to put up, forcing the banks to liquidate the positions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Grab to Go Public in Partnership with Altimeter (AGC) for Equity Value of $39.6 Billion
- Amyris (AMRS) Prices $300M Public Offering (Secondary and Primary) of Common Stock at $15.75/sh
- Novo Integrated Sciences (NVOS) Prices $8.0 Million Registered Direct Offering
Create E-mail Alert Related Categories13Gs, Hedge Funds, Trader Talk
Related EntitiesMorgan Stanley, 13G
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!